XERS 250117 2.00C (XERS250117C2000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

XERS250117C2000

Watchlist

1.60
+0.07+4.58%

15min DelayClose Jan 6 16:00 ET

1.60High1.60Low

Intraday

5D
Daily

News

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Businesswire16:15 ET
Express News | Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters16:15 ET
Earnings Call Summary | Xeris Pharmaceuticals(XERS.US) Q3 2024 Earnings Conference
moomoo AIDec 30, 2024 06:54 ET · Conference Call
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
BusinesswireNov 26, 2024 07:00 ET
When Will Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Become Profitable?
Simply Wall StNov 16, 2024 08:47 ET
Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $5
Moomoo NewsNov 11, 2024 09:31 ET · Ratings

Comments

earf321

Oct 17, 2024 13:21

$Xeris Pharmaceuticals (XERS.US)$ when will we see a new record high?

Trytosaveabit

Jul 8, 2024 06:14

Hmm

$Xeris Pharmaceuticals (XERS.US)$ Xeris Biopharma Reports Preliminary Q2 Total Revenue To Exceed $47M, Representing Over 23% Growth Over Last Year; Estimate $44.894M

Trytosaveabit

May 30, 2024 13:16

$Xeris Pharmaceuticals (XERS.US)$ And you were doing so lovely! Oh well still a nice PI on fairly benign PR as far as a catalyst for moving up

Trytosaveabit

May 30, 2024 06:35

Update

$Xeris Pharmaceuticals (XERS.US)$ Xeris Biopharma Holdings Inc - FDA End-of-Phase 2 Interaction to Facilitate a Phase 3 Pivotal Study Program Is Expected by Year-End

Jaguar8

May 30, 2024 06:31

NEWS

$Xeris Pharmaceuticals (XERS.US)$
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
Xeris Biopharma announced positive topline results from its Phase 2 study of XP-8121, a once-weekly subcutaneous levothyroxine (SC) formulation. The study showed that XP-8121 provides predictable bioavailability and sustained levothyroxine levels, achieving normalized TSH/T4 levels with 45% less drug...